What question did this study set out to answer?

June 13, 2026Neurology

ORATORIO-HAND: Results of the Primary Analysis of Ocrelizumab vs Placebo in Primary Progressive Multiple Sclerosis, Including Older Patients and Those With More Advanced Disease (S40.001)

View Full Paper

Ask AI

Bookmark

The aim is to assess the efficacy and safety of ocrelizumab in patients with primary progressive multiple sclerosis.
Randomized trial (NCT04035005) assessing patients with primary progressive multiple sclerosis.
Inclusion of older patients and those with advanced disease.
Comparison of ocrelizumab with placebo.
Ocrelizumab demonstrated significant efficacy in reducing disease progression in patients with primary progressive multiple sclerosis.
Safety profile of ocrelizumab was consistent with previous findings, with manageable adverse effects reported.

Implication

Randomized trial evaluates efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, suggesting potential benefits for older patients and those with advanced disease.

Abstract

ORATORIO-HAND (NCT04035005) evaluated the efficacy and safety of ocrelizumab in patients with primary progressive multiple sclerosis (pwPPMS), including older pwPPMS and those with more-advanced disease.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Giovannoni et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf300faef96ed7f055938 https://doi.org/10.1212/wnl.0000000000215551

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial evaluates efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, suggesting potential benefits for older patients and those with advanced disease.

ORATORIO-HAND: Results of the Primary Analysis of Ocrelizumab vs Placebo in Primary Progressive Multiple Sclerosis, Including Older Patients and Those With More Advanced Disease (S40.001)

Key Points

Implication

Abstract

Discussion

Cite This Study

ORATORIO-HAND: Results of the Primary Analysis of Ocrelizumab vs Placebo in Primary Progressive Multiple Sclerosis, Including Older Patients and Those With More Advanced Disease (S40.001)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading